Navigation Links
Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
Date:9/23/2009

LACHEN, SWITZERLAND and HOBOKEN, N.J., Sept. 23 /PRNewswire/ -- Octapharma AG recently submitted its Biological License Application for octagam(R) 10% (human normal intravenous immunoglobulin, liquid) to the U.S. Food and Drug Administration (FDA) with the goal of expanding the biopharmaceutical company's U.S. immune globulin therapy portfolio by early 2010. The application was submitted for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), a blood-clotting disorder that can result in excessive bruising and bleeding.

"We are extremely pleased with the BLA submission for octagam 10% and look forward to advancing Octapharma's firm commitment to providing immune globulin therapy in the U.S. marketplace," said Octapharma USA President Flemming Nielsen. "The expected introduction of octagam 10% will provide yet another immune globulin intravenous (IGIV) product option for patients that further builds on the success already achieved with the octagam product line both globally and in the U.S."

In 2004, Octapharma, one of the largest plasma products manufacturers in the world, gained U.S. approval from the FDA for its IGIV product, octagam(R) (immune globulin intravenous [human] 5%). The therapy, which treats disorders of the immune system, has
'/>"/>

SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations
2. Octapharma USA Retains Yankee Public Relations as its Agency of Record
3. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
4. Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract
5. Octapharma Joins Biotechnology Industry Organization
6. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
7. DIA/FDA/PhRMA Conference To Expand The Role Of Modeling And Simulation In Clinical Drug Development
8. Medelis Expands CRO Services to Medical Devices, Appoints Dr. Inder Makin as VP
9. PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says
10. Toshos Satisfaction With Health Robotics Steers the Japanese Pharmacy Automation Leader to Renew and to Expand its I.V. Automation Strategic Partnership
11. OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
(Date:9/30/2014)... 30, 2014 Nematicide is a type ... are microscopic parasitic roundworms, found in massive quantities ... plants and animals. Nematicides have tended to be ... promoting migration through the soil. A single gram ... nematodes. With more than 10,000 species classified, they ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... , , , ... the world,s leading research and advisory firms focusing on pharmaceutical ... lost substantial patient share in second- and third-line therapy since ... is most likely attributed to the publication of the ENHANCE ...
... , EMERYVILLE, Calif., Aug. 12 Neurobiological Technologies, ... it has entered into an agreement to terminate its license ... Medical Center Corporation (CMCC). Pursuant to the termination of ... final payment to NTI in satisfaction of all its royalty ...
... ... and lost each month, though the average of new jobs in the industry remains at 20,000 ... the U.S. However, companies ancillary to health care, such as insurers, are feeling the economic pinch ... (Vocus) August 12, ...
Cached Biology Technology:Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4
(Date:9/30/2014)... in German . ... expensive foods in the world. Because they grow underground, people ... distinctive smell of truffles is not only of interest to ... direction of the Goethe University Frankfurt have discovered that the ... which are trapped inside truffle fruiting bodies. , White truffles ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... is the first handbook of its kind, introducing ... microcirculation. Clearly structured throughout, this book is ... on microcirculation imaging. , Author Professor Martin J. ... explores everything from basic research to medical applications. ...
... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the 2012 Genetics Society of America (GSA) Yeast Genetics ... 31 August 5, 2012. These awards are ... postdoctorates and scientists into the mainstream of the basic ...
... from the fields of social, biological and medical science ... to discuss how they can cooperate to improve our ... influence how our genetic inheritance is expressed (epigenetics). This ... epigenetic changes have for such key social policy issues ...
Cached Biology News:World experts meet in Edinburgh to consider how life experiences impact on our genes 2
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
... I Large (Klenow) Fragment, Exonuclease Minus, is ... the 5´→3´ and the 3´→5´ exonuclease activities ... I (1,2). It is used for random ... amplification (5). Klenow Fragment, Exonuclease Minus, will ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: